Skip to main content

Advertisement

SpringerLink
Log in

Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of B cell lymphomas. MicroRNA expression provides a new and interesting tool for understanding the biology and clinical course of DLBCL. The present study presents microRNA-129-5p expression data from DLBCL patients treated with CHOP or R-CHOP. Patients with low microRNA-129-5p expression had a median survival of 23 months and a significantly shorter overall survival (P = 0.0042) compared to patients with high microRNA-129-5p expression, who had a median survival of 58 months. We also found that patients treated with R-CHOP only and displaying low microRNA-129-5p expression had a significantly shorter overall survival compared to patients with high microRNA-129-5p expression; all such patients were still alive at the time of last follow-up (P = 0.043). No significant difference was found among microRNA-129-5p expression in tumor tissue, the tissue surrounding the tumor, and normal controls. To our knowledge, this is the first report to show that the expression of microRNA-129-5p can affect the clinical outcome of DLBCL patients and that microRNA-129-5p may be involved in the biology of DLBCL development, although larger studies are necessary to confirm this. Further investigations may also help to elucidate the biological role of microRNA-129-5p in DLBCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Habermann TM, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–7.

    Article  PubMed  CAS  Google Scholar 

  2. Rosenwald A, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med. 2002;346(25):1937–47.

    Article  PubMed  Google Scholar 

  3. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.

    Article  PubMed  CAS  Google Scholar 

  4. Ninan MJ, Wadhwa PD, Gupta P. Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leuk lymphoma. 2011;52(3):360–73.

    Article  PubMed  Google Scholar 

  5. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126–39.

    Article  PubMed  CAS  Google Scholar 

  6. Valencia-Sanchez MA, et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515–24.

    Article  PubMed  CAS  Google Scholar 

  7. Davis-Dusenbery BN, Hata A. MicroRNA in cancer: the involvement of aberrant microrna biogenesis regulatory pathways. Genes Cancer. 2010;1(11):1100–14.

    Article  PubMed  CAS  Google Scholar 

  8. Hobert O. Common logic of transcription factor and microRNA action. Trends Biochem Sci. 2004;29(9):462–8.

    Article  PubMed  CAS  Google Scholar 

  9. Alencar AJ, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 2011;17(12):4125–35.

    Article  PubMed  CAS  Google Scholar 

  10. Calin GA, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New Engl J Med. 2005;353(17):1793–801.

    Article  PubMed  CAS  Google Scholar 

  11. Marcucci G, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. New Engl J Med. 2008;358(18):1919–28.

    Article  PubMed  CAS  Google Scholar 

  12. Montes-Moreno S, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118(4):1034–40.

    Article  PubMed  CAS  Google Scholar 

  13. Schwind S, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(36):5257–64.

    Article  PubMed  CAS  Google Scholar 

  14. Yanaihara N, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–98.

    Article  PubMed  CAS  Google Scholar 

  15. Liao R, et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem. 2008;104(3):805–17.

    Article  PubMed  CAS  Google Scholar 

  16. Wu J, et al. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle. 2010;9(9):1809–18.

    Article  PubMed  CAS  Google Scholar 

  17. Huang YW, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009;69(23):9038–46.

    Article  PubMed  CAS  Google Scholar 

  18. Nicoloso MS, et al. MicroRNAs–the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9(4):293–302.

    Article  PubMed  CAS  Google Scholar 

  19. Shen R, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394(4):1047–52.

    Article  PubMed  CAS  Google Scholar 

  20. Tsai KW, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 2011;129(11):2600–10.

    Article  PubMed  CAS  Google Scholar 

  21. Dyrskjot L, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851–60.

    Article  PubMed  CAS  Google Scholar 

  22. Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

    Article  PubMed  CAS  Google Scholar 

  23. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.

    Article  PubMed  CAS  Google Scholar 

  24. Lawrie CH, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009;13(7):1248–60.

    Article  PubMed  CAS  Google Scholar 

  25. Castillo JJ, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012;36(4):413–7.

    Article  PubMed  Google Scholar 

  26. Choi WW, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494–502.

    Article  PubMed  CAS  Google Scholar 

  27. Meyer SU, et al. Profound effect of profiling platform and normalization strategy on detection of differentially expressed microRNAs–a comparative study. PLoS ONE. 2012;7(6):e38946.

    Article  PubMed  CAS  Google Scholar 

  28. Katada T, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 2009;34(2):537–42.

    PubMed  CAS  Google Scholar 

  29. Tavazoie SF, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147–52.

    Article  PubMed  CAS  Google Scholar 

  30. Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 2012;18(5):411–20.

    Article  PubMed  CAS  Google Scholar 

  31. Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: WHO classification of tumours, vol. 22008, 4th ed. Lyon: WHO; 2008. p. 439.

  32. Castillo JJ, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011;16(1):87–96.

    Article  PubMed  Google Scholar 

  33. Hoeller S, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol. 2010;41(3):352–7.

    Article  PubMed  Google Scholar 

  34. Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma. 2012;53(8):1586–91.

    Article  PubMed  CAS  Google Scholar 

  35. Rosato P, et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia. 2012;26(11):2343–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden

    Gustav Hedström, Ulf Thunberg, Mattias Berglund, Martin Simonsson & Gunilla Enblad

  2. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

    Rose-Marie Amini

  3. Rudbeck Laboratory, Departments of Oncology, Radiology and Clinical Immunology, Uppsala University, SE, 751 85, Uppsala, Sweden

    Gustav Hedström

Authors
  1. Gustav Hedström
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulf Thunberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mattias Berglund
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Simonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rose-Marie Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gunilla Enblad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gustav Hedström.

Additional information

G. Hedström and U. Thunberg have contributed equally as first authors.

About this article

Cite this article

Hedström, G., Thunberg, U., Berglund, M. et al. Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL). Int J Hematol 97, 465–471 (2013). https://doi.org/10.1007/s12185-013-1303-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-013-1303-2

Keywords

Search

Navigation